Comparative Pharmacology
Head-to-head clinical analysis: EFFIENT versus INTEGRILIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EFFIENT versus INTEGRILIN.
EFFIENT vs INTEGRILIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prasugrel is a thienopyridine prodrug that irreversibly inhibits the P2Y12 receptor on platelets, reducing ADP-mediated platelet aggregation.
Reversible antagonist of the platelet glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation by preventing fibrinogen binding.
Loading dose: 60 mg orally once. Maintenance: 10 mg orally once daily. In patients weighing <60 kg, maintenance dose is 5 mg orally once daily.
Acute coronary syndrome: IV bolus of 180 mcg/kg, followed by continuous IV infusion of 2 mcg/kg/min for up to 72 hours. Percutaneous coronary intervention: IV bolus of 180 mcg/kg immediately before PCI, followed by continuous IV infusion of 2 mcg/kg/min for up to 18-24 hours, with a second 180 mcg/kg bolus 10 minutes after the first.
None Documented
None Documented
The terminal elimination half-life of the active metabolite is about 7.6 hours (range 2-15 hours). Clinically, this supports once-daily dosing.
Terminal elimination half-life: ~2.5 hours (2-3 hours) after intravenous administration; clinical context: rapid clearance allows return of platelet function within 4 hours after infusion cessation.
Approximately 68% of the dose is excreted in urine as inactive metabolites, and about 27% in feces.
Renal: ~50% as unchanged drug and metabolites, Biliary/fecal: minimal; total clearance approximately 55-58% renal.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent